Biotechnology firm ProBioGen has signed a strategic production agreement with Boehringer Ingelheim.
Subscribe to our email newsletter
Under the agreement, ProBioGen will integrate some of Boehringer’s technologies to accommodate a seamless process and technology transfer from pilot and medium-scale to commercial-scale production capacities.
ProBioGen’s clients will thereby gain access to Boehringer’s manufacturing technology platform and large-scale commercial production. In addition, Boehringer’s clients and partners will benefit from ProBioGen’s expertise in process development and manufacturing.
Michael Schlenk, CEO of ProBioGen, said: “ProBioGen’s strategic production alliance with Boehringer Ingelheim is an important milestone in our commercial strategy. For one, our clients will gain access to one of the leading commercial-scale production platforms, but we will also be able to expand our client base and have started to build additional production capabilities to meet increased client demand.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.